Events And
Presentations

NASH-TAG Conference

Jan 04 - Jan 06, 2024

Presentation: Pemvidutide-Induced Liver Fat Reduction in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease Correlates with Improvements in Non-Invasive Markers of Inflammation and Fibrosis: Results of a 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (abstract #51)

Authors: Stephen A. Harrison, Shaheen Tomah, John J. Suschak, Jonathan Kasper, M. Scot Roberts, M. Scott Harris, Sarah K. Browne

Supporting Materials

 

Investor Contact

Richard Eisenstadt
Chief Financial Officer

Email: reisenstadt@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe